Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
This article was originally published in The Tan Sheet
Executive Summary
The "behavior modification" effect ofXenical adverse events could help allay concerns that OTC availability would lead to people using orlistat without making appropriate adjustments to their diets, according to the principal investigator of a study on the drug
You may also be interested in...
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say